Company intelligence / Profile preview

SuviCa Inc.

Boulder, Colorado, United Statessuvica.com ↗

Ownership: Private
Employees: ~4
Development stage: Preclinical

Overview

Lead drug candidate SVC112 has shown compelling efficacy and safety profiles and has entered the NCI Experimental Therapeutics Program for development in salivary gland cancer

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

bouvardin

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

National Cancer InstituteUniversity of Colorado

Beyond the preview

Go deeper on SuviCa Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SuviCa Inc..

Explore the full profile